Ángel Guerrero‐Zotano

Author

Fundación Instituto Valenciano de Oncología ORCID

Also Known As

A Guerrero-Zotano, A. Guerrero Zotano, A. Guerrero zotano, A. Guerrero-Zotano, A. L. Guerrero-Zotano, Andrew Tutt, Angel Guerrero Zotano, Angel Guerrero-Zotano, Angel L. Guerrero-Zotano, Nucíforo, Paolo

262

Publications

Citations

H-Index

Concepts

All Affiliations

Fundación Instituto Valenciano de Oncología Centro de Investigación Biomédica en Red de Cáncer GEICAM – Spanish Breast Cancer Group INCLIVA Health Research Institute Instituto de Salud Carlos III

ÁG

About

Ángel Guerrero‐Zotano is an author at Fundación Instituto Valenciano de Oncología specializing in medicine, breast cancer, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	9	9	1.4K
2	Health Sciences	5	5	688
3	Cell Biology	3	3	663
4	Public Health	1	1	19
5	Epidemiology	1	1	19

Ángel Guerrero‐Zotano

Publications

3.2K

Citations

H-Index

Page 1

	Year	Citations
MYC and MCL1 Cooperatively Promote Chemotherapy-Resistant Breast Cancer Stem Cells via Regulation of Mitochondrial Oxidative Phosphorylation Kyung‐min Lee, Jennifer M. Giltnane, Justin M. Balko, Cell Metabolism Tumor BiologyBreast OncologyMitochondrial FunctionMedicineMitochondrial Oxidative Phosphorylation	2017	625
Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial Miguel Martín, Frankie A. Holmes, Bent Ejlertsen, The Lancet Oncology 5-Year AnalysisBreast OncologyOncologyHealth SciencesClinical Trials	2017	578
Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER+ breast cancer Luigi Formisano, Yao Lu, Alberto Servetto, Nature Communications	2019	383
Intrinsic Subtypes and Gene Expression Profiles in Primary and Metastatic Breast Cancer Juan Miguel Cejalvo, Eduardo Martínez de Dueñas, Patricia Galván, Cancer Research	2017	239
Genomic and Transcriptomic Analyses of Breast Cancer Primaries and Matched Metastases in AURORA, the Breast International Group (BIG) Molecular Screening Initiative Philippe Aftimos, Mafalda Oliveira, Alexandre Irrthum, Cancer Discovery	2021	169
Phase III Trial of Adjuvant Capecitabine After Standard Neo-/Adjuvant Chemotherapy in Patients With Early Triple-Negative Breast Cancer (GEICAM/2003-11_CIBOMA/2004-01) Aňa Lluch, Carlos H. Barrios, Laura Torrecillas, Journal of Clinical Oncology	2019	143
Palbociclib in combination with endocrine therapy versus capecitabine in hormonal receptor-positive, human epidermal growth factor 2-negative, aromatase inhibitor-resistant metastatic breast cancer: a phase III randomised controlled trial—PEARL Miguel Martín, Christoph Zielinski, Manuel Ruíz‐Borrego, Annals of Oncology	2020	130
Association of FGFR1 with ERα Maintains Ligand-Independent ER Transcription and Mediates Resistance to Estrogen Deprivation in ER+ Breast Cancer Luigi Formisano, Kimberly M. Stauffer, Christian D. Young, Clinical Cancer Research	2017	123
A polymorphism at the 3'-UTR region of the aromatase gene defines a subgroup of postmenopausal breast cancer patients with poor response to neoadjuvant letrozole Zaida García‐Casado, Ángel Guerrero‐Zotano, Antonio Llombart‐Cussac, BMC Cancer	2010	72
Nuclear FGFR1 Regulates Gene Transcription and Promotes Antiestrogen Resistance in ER+ Breast Cancer Alberto Servetto, Rahul K. Kollipara, Luigi Formisano, Clinical Cancer Research	2021	70

Page 1